Immunoglobulin A Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025

  • ID: 4517529
  • Report
  • 130 pages
  • P&S Market Research
1 of 3
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the period 2016 - 2025.

Insights on Pipeline Segments

The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.

Positive Clinical Trial Results Propelling the IgA Nephropathy Pipeline Growth

The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, in May 2017 OMS721, a drug candidate developed by the Omeros Corporation demonstrated positive clinical trial results in the treatment of patients with IgA nephropathy. In December 2016, Anthera Pharmaceuticals, Inc. presented positive clinical trial results of blisibimod in 48-week, Phase II study in the treatment of patients with IgA nephropathy.

Promising Targets Spur the IgA Nephropathy Pipeline Growth

Companies are developing drugs with promising targets for the treatment of the disease. The potential targets may possibly stop or slow the progression of the disease with better efficacy and less side effects. Potential targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS), melanocortin receptors, and NF-?B signaling can also prove to be effective in IgA nephropathy treatment, since clinical trials of drug candidates meant to act on these targets have shown promising results. This is encouraging companies to further invest in their pipeline to develop drugs acting on new targets, thereby, fueling the growth of the pipeline.

Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline

Various new technologies are being used by the companies for the development of drugs to treat IgA nephropathy. For instance, TARGIT drug delivery technology is being used by Calliditas Therapeutics AB for the development of novel drug therapies.
Some of the key players developing drugs for the treatment of IgA nephropathy include Mallinckrodt plc, Merck KGaA, Novartis AG, and Shire plc.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.1.1 Secondary Sources for Epidemiology Analysis
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type
2.2.2 KOLs Validation
2.3 Coverage of Epidemiology Analysis
2.4 Forecast Methodology for Epidemiology Analysis
2.5 Assumptions for Epidemiology Analysis

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Causes
4.3 Signs and Symptoms
4.4 Pathophysiology
4.5 Diagnosis
4.6 Treatment
4.7 Epidemiology
4.8 Key Drivers
4.8.1 No Specific Treatment
4.8.2 Driver 2
4.9 Key Barrier
4.9.1 No Early Signs or Symptoms
4.1 IgA Nephropathy Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company

5. IgA Nephropathy Epidemiology Overview
5.1 IgA Nephropathy Epidemiology Forecast for 7MM
5.1.1 IgA Nephropathy Epidemiology Forecast for the U.S.
5.1.2 IgA Nephropathy Epidemiology Forecast for Japan
5.1.3 IgA Nephropathy Epidemiology Forecast for EU5
5.1.3.1 IgA nephropathy epidemiology for the U.K.
5.1.3.2 IgA nephropathy epidemiology for Germany
5.1.3.3 IgA nephropathy epidemiology for France
5.1.3.4 IgA nephropathy epidemiology for Italy
5.1.3.5 IgA nephropathy epidemiology for Spain

6. Immunoglobulin a (IgA) Nephropathy Therapeutics Pipeline Analysis by Phase (2018)
6.1 Phase III
6.1.1 ACTH (Acthar) Gel
6.1.1.1 Clinical trials
6.1.1.2 Clinical results
6.1.1.3 Strategic development
6.1.2 XX
6.1.2.1 Clinical trials
6.1.2.2 Clinical results
6.1.2.3 Strategic development
6.1.2.4 Designation
6.1.2.5 Patent
6.1.2.6 Financing
6.1.2.7 Technology
6.1.3 XX
6.1.3.1 Clinical trials
6.1.3.2 Clinical results
6.1.3.3 Strategic development
6.2 Phase II/III
6.2.1 XX
6.2.1.1 Clinical trials
6.2.1.2 Clinical results
6.2.1.3 Strategic development
6.3 Phase II
6.3.1 Atacicept
6.3.1.1 Clinical trials
6.3.2 XX
6.3.2.1 Clinical trials
6.3.2.2 Clinical results
6.3.3 XX
6.3.3.1 Clinical trials
6.3.4 XX
6.3.4.1 Clinical trials
6.3.5 XX
6.3.5.1 Clinical trials
6.3.6 XX
6.3.6.1 Clinical trials
6.3.6.2 Strategic development
6.4 Pre-Clinical
6.4.1 IgA Protease
6.4.1.1 Grant
6.4.2 XX
6.4.3 XX
6.4.3.1 Pre- Clinical study
6.4.3.2 Strategic development
6.4.3.3 Technology
6.4.4 XX
6.5 Unknown
6.5.1 IL-6 antibody
6.5.1.1 Patent
6.5.2 XX
6.5.3 XX
6.6 Discovery
6.6.1 XX
6.7 Inactive
6.7.1 XX
6.7.1.1 Clinical trials
6.7.1.2 Strategic development
6.7.2 XX
6.7.2.1 Clinical trials
6.7.3 XX
6.7.3.1 Clinical trials
6.7.4 XX
6.7.4.1 Clinical trials
6.8 Discontinued
6.8.1 XX
6.8.1.1 Clinical trials
6.8.2 XX

7. Clinical Trials Review
7.1 Clinical Trials by Region
7.2 Clinical Trials by Trial Status

8. Competitive Landscape
8.1 Key Player Benchmarking
8.2 SWOT Analysis of IgA Nephropathy Pipeline

9. Company Profiles
9.1 Mallinckrodt plc
9.1.1 Business Overview
9.1.2 Product Offerings
9.2 Company 2
9.2.1 Business Overview
9.2.2 Product Offerings
9.3 Company 3
9.3.1 Business Overview
9.3.2 Product Offerings
9.4 Company 4
9.4.1 Business Overview
9.4.2 Product Offerings
9.5 Company 5
9.5.1 Business Overview
9.5.2 Product Offerings
9.6 Company 6
9.6.1 Business Overview
9.6.2 Product Offerings
9.7 Company 7
9.7.1 Business Overview
9.7.2 Product Offerings
9.8 Company 8
9.8.1 Business Overview
9.8.2 Product Offerings

10. Appendix
10.1 Abbreviation
10.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Iga Nephropathy Therapeutics, by Company (2018)
Table 2 Iga Nephropathy Epidemiology For 7Mm (2016-2025)
Table 3 Iga Nephropathy Epidemiology For the U.S. (2016-2025)
Table 4 Iga Nephropathy Epidemiology Forecast For Japan (2016-2025)
Table 5 Iga Nephropathy Epidemiology For Eu5 (2016-2025)
Table 6 Iga Nephropathy Epidemiology For the U.K (2016-2025)
Table 7 Iga Nephropathy Epidemiology For Germany (2016-2025)
Table 8 Iga Nephropathy Epidemiology For France (2016-2025)
Table 9 Iga Nephropathy Epidemiology For Italy (2016-2025)
Table 10 Iga Nephropathy Epidemiology For Spain (2016-2025)
Table 11 Description of Acth (Acthar) Gel
Table 12 Clinical Trials of Acth (Acthar) Gel
Table 13 Description of Xx
Table 14 Clinical Trials of Xx
Table 15 Description of Xx
Table 16 Clinical Trials of Xx
Table 17 Description of Xx
Table 18 Clinical Trials of Xx
Table 19 Description of Atacicept
Table 20 Clinical Trials of Atacicept
Table 21 Description of Xx
Table 22 Clinical Trials of Xx
Table 23 Description of Xx
Table 24 Clinical Trials of Xx
Table 25 Description of Xx
Table 26 Clinical Trials of Xx
Table 27 Description of Xx
Table 28 Clinical Trials of Xx
Table 29 Description of Xx
Table 30 Clinical Trials of Xx
Table 31 Description of Iga Protease
Table 32 Description of Xx
Table 33 Description of Xx
Table 34 Description of Xx
Table 35 Description of Il-6 Antibody
Table 36 Description of Xx
Table 37 Description of Xx
Table 38 Description of Xx
Table 39 Description of Xx
Table 40 Clinical Trials of Xx
Table 41 Description of Xx
Table 42 Clinical Trials of Xx
Table 43 Description of Xx
Table 44 Clinical Trials of Xx
Table 45 Description of Xx
Table 46 Clinical Trials of Xx
Table 47 Description of Xx
Table 48 Clinical Trials of Xx
Table 49 Description of Xx
Table 50 Clinical Trials of Xx
Table 51 Mallinckrodt Plc - At a Glance
Table 52 Company 2 - At a Glance
Table 53 Company 3 - At a Glance
Table 54 Company 4 - At a Glance
Table 55 Company 5 - At a Glance
Table 56 Company 6 - At a Glance
Table 57 Company 7 - At a Glance
Table 58 Company 8 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Pathophysiology of Iga Nephropathy
Fig 5: Treatment Algorithm of Iga Nephropathy
Fig 6: Iga Nephropathy Drug Candidates Under Development (2018)
Fig 7: Iga Nephropathy Pipeline Split, by Molecule Type (2018)
Fig 8: Iga Nephropathy Pipeline Split, by Route of Administration (2018)
Fig 9: Total Number of Prevalent Cases For 7Mm (2016 & 2025)
Fig 10: Iga Nephropathy Prevalence Rate In 7Mm (2016-2025)
Fig 11: Iga Nephropathy Epidemiology For 7Mm (2016-2025)
Fig 12: Iga Nephropathy Epidemiology For the U.S. (2016-2025)
Fig 13: Iga Nephropathy Epidemiology Forecast For Japan (2016-2025)
Fig 14: Iga Nephropathy Epidemiology For Eu5 (2016-2025)
Fig 15: Iga Nephropathy Epidemiology For the U.K. (2016-2025)
Fig 16: Iga Nephropathy Epidemiology For Germany (2016-2025)
Fig 17: Iga Nephropathy Epidemiology For France (2016-2025)
Fig 18: Iga Nephropathy Epidemiology For Italy (2016-2025)
Fig 19: Iga Nephropathy Epidemiology For Spain (2016-2025)
Fig 20: Phase Ii Results of Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx
Fig 21: Phase Ii Results of Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx Xx
Fig 22: Phase Ii and Follow-Up Results Xx Xx Xx
Fig 23: Breakdown of Clinical Trials, by Region
Fig 24: Breakdown of Clinical Trials, by Trial Status
Fig 25: Key Player Benchmarking
Fig 26: SWOT Analysis of Iga Nephropathy Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll